Literature DB >> 7784076

Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.

F Goubin1, B Ducommun.   

Abstract

Members of the recently discovered family of cyclin-dependent kinases inhibitors (CKIs) appear to play an essential regulatory role in the control of cell proliferation. To investigate the molecular basis of the interaction between these proteins and the cyclin-dependent kinases (CDKs), we performed a systematic mutagenesis of the CKI family member p21Cip1 using the alanine-scanning strategy. We have examined the interaction between in vitro translated human cdk2, cyclins A and D1, purified proliferating cell nuclear antigen (PCNA) and a set of human p21Cip1 mutants fused to glutathione S-transferase. Independent domains that are required for the interaction with cdk2 and with PCNA have been identified. The cdk2 binding domain is located in the N-terminal part of the protein, between residues 45 and 60, a region that is fully conserved in the p27Kip1 inhibitor. A PCNA binding region was localised to the C-terminus of the protein, between residues 142 and 163. These findings define protein motifs that are highly conserved between members of the CKI family and that are likely to play an essential function in the regulation of the G1/S transition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784076

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Binding of calmodulin to the carboxy-terminal region of p21 induces nuclear accumulation via inhibition of protein kinase C-mediated phosphorylation of Ser153.

Authors:  Aina Rodríguez-Vilarrupla; Montserrat Jaumot; Neus Abella; Núria Canela; Sonia Brun; Carmen Díaz; Josep M Estanyol; Oriol Bachs; Neus Agell
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

2.  Analysis of wild-type and mutant p21WAF-1 gene activities.

Authors:  J Lin; C Reichner; X Wu; A J Levine
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

4.  Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice.

Authors:  Robert W Engelman; Rosalind J Jackson; Domenico Coppola; Walker Wharton; Alan B Cantor; W Jack Pledger
Journal:  Exp Mol Pathol       Date:  2007-01-04       Impact factor: 3.362

5.  Comparative molecular and functional analyses of the tobacco cyclin-dependent kinase inhibitor NtKIS1a and its spliced variant NtKIS1b.

Authors:  Sophie Jasinski; Claudette Perennes; Catherine Bergounioux; Nathalie Glab
Journal:  Plant Physiol       Date:  2002-12       Impact factor: 8.340

6.  Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells.

Authors:  D Agrawal; P Hauser; F McPherson; F Dong; A Garcia; W J Pledger
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

7.  p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.

Authors:  M S Woo; I Sánchez; B D Dynlacht
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

8.  E7 abolishes raf-induced arrest via mislocalization of p21(Cip1).

Authors:  Thomas F Westbrook; Don X Nguyen; Barry R Thrash; Dennis J McCance
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain.

Authors:  E Warbrick; W Heatherington; D P Lane; D M Glover
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

10.  A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo.

Authors:  J Chen; R Peters; P Saha; P Lee; A Theodoras; M Pagano; G Wagner; A Dutta
Journal:  Nucleic Acids Res       Date:  1996-05-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.